Retraction: Comparative Effects of Risedronate and Calcitriol on Cancellous Bone in Rats With Glucocorticoid-Induced Osteopenia (J Nutr Sci Vitaminol (Tokyo), (2006) 52, 1, (21-27), 10.3177/jnsv.52.21);Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia

Journal of Nutritional Science and Vitaminology

Volumn 52, Issue 1, 2006, Pages 21-27

  Iwamoto, Jun ^a   Seki, Azusa ^b   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^c   Yamada, Harumoto ^d   Shen, Chwan Li ^e   Yeh, James K ^f  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hamri Co Ltd   (Japan)

^c Mitate Hospital   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Calcitriol; Cancellous osteopenia; Glucocorticoid; Rat; Risedronate

Indexed keywords

CALCITRIOL; DRUG VEHICLE; GLUCOCORTICOID; METHYLPREDNISOLONE SODIUM SUCCINATE; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METABOLISM; BONE TURNOVER; CANCELLOUS BONE; COMPRESSIVE STRENGTH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FEMUR; METAPHYSIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; TIBIA; TRABECULAR BONE;

ANIMALIA;

EID: 33645771945     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.66.91     Document Type: Erratum

References (30)

1. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. 2000. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15: 993-1000.
2. Clowes JA, Peel N, Eastell R. 2001. Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 13: 326-332.
3. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA. 2000. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67: 277-285.
4. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Glucocorticoid-Induced Osteoporosis Intervention Study Group. 1998. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339: 292-299.
5. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A. 2001. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44: 202-211.
6. 3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15: 589-602.
7. Amin S, Lavalley MP, Simms RW, Felson DT. 2002. The comparative efficacy of drug therapy used for the management of corticosteroid-induced osteoporosis: a metaregression. J Bone Miner Res 17: 1512-1526.
8. Ito M, Nishida A, Aoyagi K, Uetani M, Hayashi K, Kawase M. 2005. Effects of risedronate on trabecular microstructure and biomechanical properties in ovariectomized rat tibia. Osteoporos Int (online publication).
9. 3. J Bone Miner Res 17: 1498-1511.
10. 3 modulates glucocorticoid-induced alteration in serum bone Gla protein and bone histomorphometry. Endocrinology 120: 531-536.
11. 2 and risedronate administration on cancellous bone in older female rats. Bone 15: 489-496.
12. Mosekilde L, Thomsen JS, Mackey MS, Phipps RJ. 2000. Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 27: 639-645.
13. Iwamoto J, Seid A, Takeda T, Shen CL, Yeh JK. 2005. Effects of risedronate and calcitriol on the structure and mechanical properties of cancellous bone in glucocorticoid-treated rats. 35th Sun Valley Workshop of Skeletal Biology (online abstract).
14. Erben RG. 1997. Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem 45: 307-313.
15. Prakasam G, Yeh JK, Chen MM, Castro-Magana M, Liang CT, Aloia JF. 1999. Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats. Bone 24: 491-497.
16. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASMBR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610.
17. 2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 31: 575-581.
18. Furuichi H, Fukuyama R, Izumo N, Fujita T, Kohno T, Nakamuta H, Koida M. 2000. Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats. Bio Pharm Bull 23: 946-951.
19. Nitta T, Fukushima T, Nakamuta H, Koida M. 1999. Glucocorticoid-induced secondary osteopenia in female rats: a time course study as compared with ovariectomy-induced osteopenia and response to salmon calcitonin. Jpn J Pharmacol 79: 379-386.
20. Noa M, Mendoza S, Mas R, Mendoza N, Leon F. 2004. Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats. Drugs R D 5: 281-290.
21. Ortoft G, Oxlund H. 1996. Qualitative alterations of cortical bone in female rats after long-term administration of growth hormone and glucocorticoid. Bone 18: 581-590.
22. Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y. 1996. Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res 11: 325-336.
23. Ikeda S, Morishita Y, Tsutsumi H, Ito M, Shiraishi A, Arita S, Akahoshi S, Narusawa K, Nakamura T. 2003. Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs. Bone 33: 779-787.
24. Chavassieux P, Buffet A, Vergnaud P, Garnero P, Meunier PJ. 1997. Short-term effects of corticosteroids on trabecular bone remodeling in old ewes. Bone 20: 451-455.
25. Manolagas SC, Weinstein RS. 1999. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14: 1061-1066.
26. 2. J Bone Miner Metab 22: 404-414.
27. Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, Nakamura T. 2002. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 71: 69-79.
28. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. 2000. Alfacalcidol inhibits bone resorption and stimulate formation in an ovariectomized rats model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 15: 770-779.
29. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, Hamdy NA, Malice MP, Freedholm D, Meunier PJ. 2000. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 15: 754-762.
30. Epstein S. 2005. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 80: 379-388.